Longitudinal associations between MRI and cognitive changes in very early MS

Bardia Nourbakhsh, Julia Nunan-Saah, Amir Hadi Maghzi, Laura J. Julian, Rebecca Spain, Chengshi Jin, Ann Lazar, Daniel Pelletier, Emmanuelle Waubant

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. Methods: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. Results: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6% of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p <0.001). Conclusion: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalMultiple Sclerosis and Related Disorders
Volume5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Multiple Sclerosis
Magnetic Resonance Imaging
Riluzole
Brain
Placebos
Sex Education
Cognition
Longitudinal Studies
Cognitive Dysfunction

Keywords

  • Atrophy
  • MRI scans
  • Multiple sclerosis
  • Neuropsychological tests

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Longitudinal associations between MRI and cognitive changes in very early MS. / Nourbakhsh, Bardia; Nunan-Saah, Julia; Maghzi, Amir Hadi; Julian, Laura J.; Spain, Rebecca; Jin, Chengshi; Lazar, Ann; Pelletier, Daniel; Waubant, Emmanuelle.

In: Multiple Sclerosis and Related Disorders, Vol. 5, 01.01.2016, p. 47-52.

Research output: Contribution to journalArticle

Nourbakhsh, B, Nunan-Saah, J, Maghzi, AH, Julian, LJ, Spain, R, Jin, C, Lazar, A, Pelletier, D & Waubant, E 2016, 'Longitudinal associations between MRI and cognitive changes in very early MS', Multiple Sclerosis and Related Disorders, vol. 5, pp. 47-52. https://doi.org/10.1016/j.msard.2015.10.010
Nourbakhsh, Bardia ; Nunan-Saah, Julia ; Maghzi, Amir Hadi ; Julian, Laura J. ; Spain, Rebecca ; Jin, Chengshi ; Lazar, Ann ; Pelletier, Daniel ; Waubant, Emmanuelle. / Longitudinal associations between MRI and cognitive changes in very early MS. In: Multiple Sclerosis and Related Disorders. 2016 ; Vol. 5. pp. 47-52.
@article{e2093042f7c04e1e95822767312b8505,
title = "Longitudinal associations between MRI and cognitive changes in very early MS",
abstract = "Objectives: Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. Methods: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. Results: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6{\%} of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p <0.001). Conclusion: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.",
keywords = "Atrophy, MRI scans, Multiple sclerosis, Neuropsychological tests",
author = "Bardia Nourbakhsh and Julia Nunan-Saah and Maghzi, {Amir Hadi} and Julian, {Laura J.} and Rebecca Spain and Chengshi Jin and Ann Lazar and Daniel Pelletier and Emmanuelle Waubant",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.msard.2015.10.010",
language = "English (US)",
volume = "5",
pages = "47--52",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Longitudinal associations between MRI and cognitive changes in very early MS

AU - Nourbakhsh, Bardia

AU - Nunan-Saah, Julia

AU - Maghzi, Amir Hadi

AU - Julian, Laura J.

AU - Spain, Rebecca

AU - Jin, Chengshi

AU - Lazar, Ann

AU - Pelletier, Daniel

AU - Waubant, Emmanuelle

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. Methods: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. Results: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6% of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p <0.001). Conclusion: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.

AB - Objectives: Cognitive dysfunction in multiple sclerosis (MS) has been primarily examined in patients with advanced disease. Our objective was to study the longitudinal associations between brain magnetic resonance imaging (MRI) metrics and neuropsychological outcomes in patients with early MS. Methods: Relapsing MS patients within 12 months of onset were enrolled in a neuroprotection trial of riluzole versus placebo with up to 36 months of follow-up. MRI metrics included percent brain volume changes measured by SIENAX normalized measurements [normalized brain parenchymal volume (nBPV), normalized normal-appearing white and gray matter volume (nNAWMV and nGMV)] and T2 lesion volume (T2LV). A neuropsychological battery was performed annually. Mixed model regression measured time trends and associations between imaging and neuropsychological outcomes, adjusting for sex, age and education level. Results: Forty-three patients (mean age 36 years; 31 females) were enrolled within 7.5 ± 4.9 months of disease onset. 11.6% of patients with baseline cognitive assessment met conservative criteria for cognitive impairment. Compared to placebo, riluzole had no significant effect on neuropsychological performance; thus, both groups were combined for the association analyses. Baseline T2LV predicted subsequent changes in PASAT (p=0.006) and SDMT (p=0.002) scores. Longitudinal changes of T2LV were associated with changes in CVLT-II (p <0.001). Conclusion: These findings suggest that cognitive impairment is relatively common in patients with very early MS. Baseline and longitudinal changes in the lesion load may be associated with some of the most frequently identified changes in cognitive function in MS.

KW - Atrophy

KW - MRI scans

KW - Multiple sclerosis

KW - Neuropsychological tests

UR - http://www.scopus.com/inward/record.url?scp=84960539834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960539834&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2015.10.010

DO - 10.1016/j.msard.2015.10.010

M3 - Article

VL - 5

SP - 47

EP - 52

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -